Abbreviations GLP1-RA: Glucagon like peptide-1 receptor agonist ASCVD: Atherosclerotic cardiovascular disease MACE: Major adverse cardiovascular events NNT: Numbers Needed to Treat MI: Myocardial Infarction CVD: Cardiovascular Disease SGLT2i: Sodium-glucose cotransporter-2 inhibitors LEADER: Liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results T2DM: Type 2 Diabetes mellitus SELECT: Semaglutide effects on cardiovascular outcomes in people with overweight or obesity PREVENT: Predicting risk of cardiovascular disease events HF: Heart Failure PRISMA: Preferred reporting items for systematic review and meta-analyses RCT: Randomized controlled trial BMI: Body mass index RR: Risk ratio NNTB: Numbers needed to benefit NNTH: Number needed to harm ROB-2: Cochrane risk of bias 2 (ROB-2) tool FLOW: Evaluate renal function with semaglutide once weekly References Federation WH
Share your victories, seek advice, and draw inspiration from the collective strength of those pursuing similar goals
Always follow your healthcare providers guidance
Tirzepatide vs Semaglutide for Microdosing How tirzepatide and semaglutide compare for GLP-1 microdosing and why menopause may affect response
This quick, confidential quiz helps us understand your health profile and determine your eligibility for prescription weight loss medications, setting the stage for a truly individualized treatment plan
As semaglutide and tirzepatide have been used by millions of people worldwide, the data on skin-related side effects has grown substantially
